Partial
Mostly Aligned
Patient Risk:
Low
Summary
Several clinical indication and dosing-related claims are supported by the provided label excerpts, but multiple claims (especially non-label patent/pricing/availability statements and a general statement about dosage selection) are not supported by the supplied prescribing information.
Category Scores
Accurate Statements
Plavix is the brand-name medication containing the active ingredient clopidogrel.
11 DESCRIPTION: "Plavix (clopidogrel tablets)"
Plavix is an antiplatelet medication.
12.1 Mechanism of Action: inhibitor of platelet activation and aggregation via P2Y12 ADP receptors
Plavix is used to reduce the rate of myocardial infarction (MI) and stroke in patients with non–ST-segment elevation acute coronary syndrome (unstable angina/NSTEMI).
1.1 Acute Coronary Syndrome (ACS) indication statement for non–ST-segment elevation ACS; administered with aspirin
Plavix is used to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically.
1.1 Acute Coronary Syndrome (ACS) indication statement for medically managed STEMI; administered with aspirin
Plavix is used in individuals with established peripheral arterial disease.
1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: established peripheral arterial disease
Plavix is used in individuals with a history of recent myocardial infarction.
1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: history of recent MI
Plavix is used in individuals with a history of recent stroke.
1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: history of recent stroke
Plavix includes 75 mg and 300 mg tablet strengths.
11 DESCRIPTION (75 mg and 300 mg tablets described)
For patients who need antiplatelet effect within hours, Plavix is initiated with a single 300 mg oral loading dose followed by 75 mg once daily.
2.1 Acute Coronary Syndrome (also repeated in 14.1/14.2 provided dosing language)
Unsupported Statements
Generic clopidogrel contains the same active ingredient as Plavix.
The provided label excerpts do not state anything about generic clopidogrel composition or equivalence.
Generic clopidogrel is formulated to be bioequivalent to Plavix.
No bioequivalence statement is present in the provided label excerpts.
Plavix is used to help prevent blood clots in individuals who have had a recent heart attack.
The label provided states reduction in the rate of MI and stroke; it does not use the term "blood clots".
Plavix is used to help prevent blood clots in individuals who have had a recent stroke.
The label provided states reduction in the rate of MI and stroke; it does not use the term "blood clots".
Plavix is used in patients with acute coronary syndrome who are undergoing certain procedures, like angioplasty.
The provided ACS indication includes patients "to be managed with coronary revascularization" but does not specifically mention angioplasty.
The specific dosage prescribed depends on the patient's medical condition and treatment plan.
The provided label excerpts show regimen examples (loading vs maintenance) but do not explicitly state that dosage depends on patient condition/treatment plan.
The patent protection for Plavix has largely expired, which has allowed for the introduction of generic versions.
No patent/generic introduction statement is present in the provided label excerpts.
Generic versions of clopidogrel are typically less expensive than the brand-name drug.
Pricing/market statements are not present in the provided label excerpts.
A 90-day supply of 75 mg clopidogrel tablets might range from approximately $25 to $50 or more, depending on the retailer and any available discounts.
No pricing or cost estimates are present in the provided label excerpts.
Online pharmacies and prescription discount programs can often offer lower prices than traditional brick-and-mortar stores.
No pharmacy/discount program pricing statements are present in the provided label excerpts.
Contradictions
Important Omissions
Concomitant aspirin requirement in ACS indications (and lack of mention of aspirin in the extracted claims).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most clinical claims align directionally with provided indications/mechanism and dosing regimen structure, but several statements are unsupported by the provided label excerpts (notably generic/patent/pricing/angioplasty specificity and generalized dosage-dependence). Concomitant aspirin guidance for ACS was not reflected in the extracted claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Non-label market/patent/pricing claims and specificity gaps ("blood clots" wording; angioplasty not stated; generalized dosage-dependence not stated).
Suggested Improvement
Limit claims to those explicitly supported by the provided label excerpts (e.g., describe indications as reduction in MI and stroke per label wording; avoid generic/bioequivalence/patent/pricing statements; avoid asserting angioplasty specifically unless revascularization/angioplasty is stated; for ACS include that Plavix should be administered in conjunction with aspirin).